Screening and antitumor effect of an anti‑CTLA‑4 nanobody

Wan,Ruirong; Liu,Aiqun; Hou,Xiaoqiong; Lai,Zongqiang; Li,Jieping; Yang,Nuo; Tan,Juntao; Mo,Fengzhen; Hu,Zixi; Yang,Xiaomei; Zhao,Yongxiang; Lu,Xiaoling

doi:10.3892/or.2017.6131

Screening and antitumor effect of an anti‑CTLA‑4 nanobody

Authors:
- Ruirong Wan
- Aiqun Liu
- Xiaoqiong Hou
- Zongqiang Lai
- Jieping Li
- Nuo Yang
- Juntao Tan
- Fengzhen Mo
- Zixi Hu
- Xiaomei Yang
- Yongxiang Zhao
- Xiaoling Lu
View Affiliations

Affiliations: National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: December 4, 2017 https://doi.org/10.3892/or.2017.6131
Pages: 511-518
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytotoxic T‑lymphocyte antigen‑4 (CTLA‑4) is a critical negative regulator of immune responses. CTLA‑4 is rapidly upregulated following T‑cell activation, and then binds to B7 molecules with a higher affinity than CD28. CTLA‑4 may abolish the initiation of the responses of T cells by raising the threshold of signals required for full activation of T cells, and it also may terminate ongoing T-cell responses. This regulatory role has led to the development of monoclonal antibodies (mAbs) designed to block CTLA‑4 activity for enhancing immune responses against cancer. mAbs have several disadvantages including high production cost and unstable behavior. Nanobodies (Nbs) are single‑domain antigen‑binding fragments derived from the camelid heavy‑chain antibodies, which are highly attractive in cancer immunotherapy due to their small size, high specificity, and stability. We selected CTLA‑4‑specific Nbs from a high quality dromedary camel immune library by phage display technology. Four positive colonies were sequenced and classified based on the amino acids sequences in the CDR3 region. These Nbs recognized unique epitopes on CTLA‑4 and displayed high binding rates when used on PHA‑stimulated human T cells. Treatment of B16 melanoma‑bearing C57BL/6 mice with anti‑CTLA‑4 nanobody 16 (Nb16) delayed melanoma growth and prolonged the survival time of mice. These data indicate that anti‑CTLA‑4 Nbs selected from a high quality phage display library may be effective for the treatment of patients with tumors.

View Figures

View References

1	Peggs KS, Quezada SA, Chambers CA, Korman AJ and Allison JP: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 206:1717–1725. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD and Allison JP: Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 6:226ra322014. View Article : Google Scholar : PubMed/NCBI
3	Butte MJ, Keir ME, Phamduy TB, Sharpe AH and Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
4	Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M and Eto M: Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. Oncol Rep. 33:2947–2953. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Brug MB and Allison JP: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60:2444–2448. 2000.PubMed/NCBI
6	Van Elsas A, Hurwitz AA and Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 190:355–366. 1999. View Article : Google Scholar : PubMed/NCBI
7	Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI
8	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 23:8968–8977. 2005. View Article : Google Scholar : PubMed/NCBI
10	Fernández LÁ and Muyldermans S: Recent developments in engineering and delivery of protein and antibody therapeutics. Curr Opin Biotech. 22:839–842. 2011. View Article : Google Scholar : PubMed/NCBI
11	Saerens D, Frederix F, Reekmans G, Conrath K, Jans K, Brys L, Huang L, Bosmans E, Maes G, Borghs G and Muyldermans S: Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal Chem. 77:7547–7555. 2005. View Article : Google Scholar : PubMed/NCBI
12	Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C and Muyldermans S: Nanobodies and their potential applications. Nanomedicine. 8:1013–1026. 2013. View Article : Google Scholar : PubMed/NCBI
13	Market E and Papavasiliou FN: V(D)J recombination and the evolution of the adaptive immune system. PLoS Biol. 1:E162003. View Article : Google Scholar : PubMed/NCBI
14	Holt LJ, Herring C, Jespers LS, Woolven BP and Tomlinson IM: Domain antibodies: proteins for therapy. Trends Biotechnol. 21:484–490. 2003. View Article : Google Scholar : PubMed/NCBI
15	Muyldermans S: Nanobodies: Natural single-domain antibodies. Annu Rev Biochem. 82:775–797. 2013. View Article : Google Scholar : PubMed/NCBI
16	Gueorguieva D, Li S, Walsh N, Mukerji A, Tanha J and Pandey S: Identification of single-domain, Bax-specific intra-bodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. FASEB J. 20:2636–2638. 2006. View Article : Google Scholar : PubMed/NCBI
17	Pérez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H and Frenken LG: Thermal unfolding of a llama antibody fragment: A two-state reversible process. Biochemistry. 40:74–83. 2001. View Article : Google Scholar : PubMed/NCBI
18	Muyldermans S: Single domain camel antibodies: Current status. J Biotechnol. 74:277–302. 2001.PubMed/NCBI
19	De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S and Wyns L: Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci USA. 103:pp. 4586–4591. 2006; View Article : Google Scholar : PubMed/NCBI
20	Kijanka M, Warnders FJ, El Khattabi M, Lub-de Hooge M, van Dam GM, Ntziachristos V, de Vries L, Oliveira S and van Bergen En Henegouwen PM: Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur J Nucl Med Mol Imaging. 40:1718–1729. 2013. View Article : Google Scholar : PubMed/NCBI
21	Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H and van Dongen GA: Nanobodies targeting the hepatocyte growth factor: Potential new drugs for molecular cancer therapy. Mol Cancer Ther. 11:1017–1025. 2012. View Article : Google Scholar : PubMed/NCBI
22	De Meyer T, Eeckhout D, De Rycke R, De Buck S, Muyldermans S and Depicker A: Generation of VHH antibodies against the Arabidopsis thaliana seed storage proteins. Plant Mol Biol. 84:83–93. 2014. View Article : Google Scholar : PubMed/NCBI
23	Conrath KE, Lauwereys M, Galleni M, Matagne A, Frère JM, Kinne J, Wyns L and Muyldermans S: Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother. 45:2807–2812. 2001. View Article : Google Scholar : PubMed/NCBI
24	Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G and Muyldermans S: Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. Methods Mol Biol. 907:145–176. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhu M, Gong X, Hu Y, Ou W and Wan Y: Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. J Transl Med. 12:3522014. View Article : Google Scholar : PubMed/NCBI
26	Nevoltris D, Lombard B, Dupuis E, Mathis G, Chames P and Baty D: Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers. ACS Nano. 9:1388–1399. 2015. View Article : Google Scholar : PubMed/NCBI
27	Hernot S, Unnikrishnan S, Du Z, Shevchenko T, Cosyns B, Broisat A, Toczek J, Caveliers V, Muyldermans S, Lahoutte T, et al: Nanobody-coupled microbubbles as novel molecular tracer. J Control Release. 158:346–353. 2012. View Article : Google Scholar : PubMed/NCBI
28	Muyldermans S, Baral T, Retamozzo VC, De Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen V, Revets H, et al: Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol. 128:178–183. 2009. View Article : Google Scholar : PubMed/NCBI
29	Curran MA, Montalvo W, Yagita H and Allison JP: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:pp. 4275–4280. 2010; View Article : Google Scholar : PubMed/NCBI
30	Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L and Matagne A: Single-domain antibody fragments with high conformational stability. Protein Sci. 11:500–515. 2002. View Article : Google Scholar : PubMed/NCBI
31	Vu KB, Ghahroudi MA, Wyns L and Muyldermans S: Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol. 34:1121–1131. 1997. View Article : Google Scholar : PubMed/NCBI
32	Vaneycken I, Govaert J, Vincke C, Caveliers V, Lahoutte T, De Baetselier P, Raes G, Bossuyt A, Muyldermans S and Devoogdt N: In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med. 51:1099–1106. 2010. View Article : Google Scholar : PubMed/NCBI
33	Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S and Conrath K: General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 284:3273–3284. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gao Y, Gao W, Chen X, Cha N, Wang X, Jia X, Wang B, Ren M and Ren J: Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. Oncol Rep. 36:1243–1250. 2016. View Article : Google Scholar : PubMed/NCBI
35	Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H and van Dongen GA: Nanobodies targeting the hepatocyte growth factor: Potential new drugs for molecular cancer therapy. Mol Cancer Ther. 11:1017–1025. 2012. View Article : Google Scholar : PubMed/NCBI